AC Immune (ACIU) Competitors

AC Immune (NASDAQ:ACIU) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.

Does the MarketBeat Community prefer ACIU or SNDX?

Syndax Pharmaceuticals received 129 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 65.37% of users gave Syndax Pharmaceuticals an outperform vote while only 62.47% of users gave AC Immune an outperform vote.

Company	Underperform	Outperform
AC Immune	Outperform Votes 258 62.47%	Underperform Votes 155 37.53%
Syndax Pharmaceuticals	Outperform Votes 387 65.37%	Underperform Votes 205 34.63%

Do institutionals & insiders have more ownership in ACIU or SNDX?

51.4% of AC Immune shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is ACIU or SNDX more profitable?

AC Immune's return on equity of -28.26% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	N/A	-28.26%	-18.98%
Syndax Pharmaceuticals	N/A	-64.34%	-57.72%

Do analysts rate ACIU or SNDX?

AC Immune presently has a consensus target price of $12.00, indicating a potential upside of 347.76%. Syndax Pharmaceuticals has a consensus target price of $36.20, indicating a potential upside of 176.76%. Given AC Immune's stronger consensus rating and higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Syndax Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Does the media favor ACIU or SNDX?

In the previous week, Syndax Pharmaceuticals had 8 more articles in the media than AC Immune. MarketBeat recorded 9 mentions for Syndax Pharmaceuticals and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.05 beat Syndax Pharmaceuticals' score of 0.42 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more volatility and risk, ACIU or SNDX?

AC Immune has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Which has higher valuation & earnings, ACIU or SNDX?

AC Immune has higher revenue and earnings than Syndax Pharmaceuticals. AC Immune is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$16.48M	16.09	-$60.41M	-$0.46	-5.83
Syndax Pharmaceuticals	N/A	N/A	-$209.36M	-$3.63	-3.60

Summary

AC Immune beats Syndax Pharmaceuticals on 11 of the 16 factors compared between the two stocks.